A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030750

Enrollment

Unknown

Registered

2020-03-13

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

common type :Immunotherapy with recombinant chimeric DC vaccine

Latent period group:Immunotherapy with recombinant chimeric DC vaccine

Normal control group:Immunotherapy with recombinant chimeric DC vaccine

Blank vaccine control group:0.9%NS

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed cases: positive nucleic acid test; 2. Aged 25-65 years; 3. Asexual difference; 4. Clinical stage (light, common type); 5. Immunology standard: peripheral blood lymphocyte was higher than the lower limit of normal;

Exclusion criteria

Exclusion criteria: 1. With complications of multiple organ failure; 2. Patients with malignant tumor; 3. Pregnant women; 4. HIV positive.

Design outcomes

Primary

Measure	Time frame
Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;	—

Countries

China

Contacts

Public ContactZhenlin Zhao

Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine

zhaozl2006@163.com+86 13828895409

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026